Trials / Completed
CompletedNCT01139931
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
Epigenetic Alterations in AML
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * Map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations. * Acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (AML). * Investigate functional relationships between genetic and epigenetic landscapes in AML. OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. Genome-wide locations of 5 histone modifications are analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data (sequence analysis, expression array, SNP array).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | DNA methylation analysis | |
| GENETIC | gene expression analysis | |
| GENETIC | microarray analysis | |
| GENETIC | polymorphism analysis | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2016-05-01
- First posted
- 2010-06-09
- Last updated
- 2016-05-18
Source: ClinicalTrials.gov record NCT01139931. Inclusion in this directory is not an endorsement.